Search: onr:"swepub:oai:prod.swepub.kib.ki.se:145621706" >
Cytomegalovirus (CM...
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study
- Article/chapterEnglish2020
Publisher, publication year, extent ...
-
2020-02-20
-
Oxford University Press (OUP),2020
Numbers
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:145621706
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:145621706URI
-
https://doi.org/10.1093/cid/ciz1210DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
BackgroundCytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically significant CMV infection (CS-CMVi).MethodsThe CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral therapy. CMV-CMI was characterized as high when the intermediate-early 1 (IE-1) antigen spot counts (SPCs) were >100 (cutoff 1) or when the IE-1 and phosphoprotein 65 antigen SPCs were both >100 SPCs per 250 000 cells (cutoff 2), and a low CMV-CMI when SPCs were below these thresholds. In this prospective multicenter study, we evaluated CMV-CMI every 2 weeks from the pretransplant period until 6 months posttransplantation in 241 allo-HCT recipients with positive CMV serostatus. The primary endpoint was CS-CMVi occurring within 2 weeks of the last measurement of CMV-CMI.ResultsCS-CMVi occurred in 70 allo-HCT recipients (29%). CMV-CMI was low in patients who experienced CS-CMVi (94%), whereas those who had a high CMV-CMI were less likely to have CS-CMVi (P < .0001). Patients with CS-CMVi had higher all-cause mortality (P = .007), especially those with low CMV-CMI (P = .035). On multivariable analysis, CMV-CMI, sex, race, antithymocyte globulin, and steroid use were independent predictors of CS-CMVi, and the time from transplant to engraftment was the only predictor of mortality.ConclusionsMeasurement of CMV-CMI using a novel ELISPOT assay would be useful clinically to monitor allo-HCT recipients and distinguish between those at risk of developing CS-CMVi and requiring antiviral prophylaxis or therapy and those who are protected.
Added entries (persons, corporate bodies, meetings, titles ...)
-
El Haddad, L
(author)
-
Winston, DJ
(author)
-
Rowley, SD
(author)
-
Mulane, KM
(author)
-
Chandrasekar, P
(author)
-
Avery, RK
(author)
-
Hari, P
(author)
-
Peggs, KS
(author)
-
Kumar, D
(author)
-
Nath, R
(author)
-
Ljungman, PKarolinska Institutet
(author)
-
Mossad, SB
(author)
-
Dadwal, SS
(author)
-
Blanchard, T
(author)
-
Shah, DP
(author)
-
Jiang, Y
(author)
-
Ariza-Heredia, E
(author)
-
Karolinska Institutet
(creator_code:org_t)
Related titles
-
In:Clinical infectious diseases : an official publication of the Infectious Diseases Society of America: Oxford University Press (OUP)71:9, s. 2365-23741537-6591
-
In:Clinical Infectious Diseases: Oxford University Press (OUP)71:9, s. 2365-23741058-4838
Internet link
Find in a library
To the university's database
- By the author/editor
-
Chemaly, RF
-
El Haddad, L
-
Winston, DJ
-
Rowley, SD
-
Mulane, KM
-
Chandrasekar, P
-
show more...
-
Avery, RK
-
Hari, P
-
Peggs, KS
-
Kumar, D
-
Nath, R
-
Ljungman, P
-
Mossad, SB
-
Dadwal, SS
-
Blanchard, T
-
Shah, DP
-
Jiang, Y
-
Ariza-Heredia, E
-
show less...
- Articles in the publication
-
Clinical infecti ...
-
Clinical Infecti ...
- By the university
-
Karolinska Institutet